2024-11-19 03:38:15
Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH
Health/ 2023-07-22
Hepagene Therapeutics Reports Positive T...

SHANGHAI,Jan. 19,2023-- Hepagene Therapeutics,Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for pat...

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Corporate/ 2023-07-24
Sun Pharma to Acquire Concert Pharmaceut...

Adds Deuruxolitinib,a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata,an Autoimmune Dermatological Disease

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release